 |
|
|
| |
Use of genotypic and maraviroc (MVC) clinical trial data to develop statistical models for predicting response to a MVC-containing regimen in a treatment-experienced (TE) population
|
| |
| |
Reported by Jules Levin, 18th Intl AIDS Conf July 18-23 2010 Vienna Austria
Pinaki Biswas1, Doug Chapman1, Xiaoyin Zhong2, Guinevere Q. Lee2, P. Richard Harrigan2, Jayvant Heera3, Hernan Valdez1
1Pfizer Inc, New York, NY, USA; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada, 3Pfizer Global Research and Development, New London, CT, USA
|
| |
|
|
|
|
|
